To gain further support of the role of the ZNF516–CtBP/LSD1/CoREST–EGFR axis in the development and progression of breast cancer and to extend our observations to a clinicopathologically relevant context, we first profiled the expression pattern of ZNF516 and EGFR in breast cancer cell lines. Here, ZNF516 is linked to breast carcinoma.